Enhanced External Counterpulsation (EECP)

Policy # 00036
Original Effective Date: 11/12/2001
Current Effective Date: 08/01/2018

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider a course of up to 35 sessions of enhanced external counterpulsation (EECP) (using FDA-approved external counterpulsation systems) to be eligible for coverage.

Patient Selection Criteria
Coverage eligibility for the use of enhanced external counterpulsation (EECP) will be considered for individuals who have severe chronic stable angina (Class III or IV per the New York Heart Association [NYHA] classification* or equivalent) and the following criteria are met:

- Patient is not considered to be suitable candidate for angioplasty or revascularization in the opinion of a cardiologist or cardiovascular surgeon, e.g. the patient is inoperable or at high risk for complications, or the coronary anatomy is not suitable for revascularization; or
- Patient continues to experience angina despite optimal pharmacologic therapy and coronary revascularization.

Note:
A single course of EECT consists of 35 one-hour treatment sessions, usually 5 sessions per week over a period of approximately 7 weeks. There is no proven benefit to extending a course of EECP beyond 35 sessions.

Repeat courses of EECP treatment will require review of supporting documentation and might be considered if patient had a significant reduction in frequency of angina symptoms/episodes and three or more months have elapsed from the prior EECP treatment.

This procedure must be performed under direct supervision of a physician. The physician must be present in the office suite and immediately available to provide assistance and direction throughout the time the personnel is performing the service.

New York Heart Association (NYHA) classification is as follows:

- Class I Mild
Patients with cardiac disease but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea or anginal pain.

Class II Mild
Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in fatigue, palpitation or dyspnea.

Class III Moderate
Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea or anginal pain.

Class IV Severe
Unable to carry out any physical activity without discomfort. Symptoms of cardiac insufficiency at rest. If any physical activity is undertaken, discomfort is increased.

When Services Are Considered Investigational
Note: Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

The use of enhanced external counterpulsation (EECP) when patient selection criteria are not met is considered to be investigational.*

Background/Overview
EECP is a noninvasive treatment that uses timed, sequential inflation of pressure cuffs on the calves, thighs, and buttocks to augment diastolic pressure, decrease left ventricular afterload and increase venous return. Augmenting diastolic pressure displaces a volume of blood backward into the coronary arteries during diastole when the heart is in a state of relaxation and the resistance in the coronary arteries is at a minimum. The resulting increase in coronary artery perfusion pressure may enhance coronary collateral development or increase flow through existing collaterals. In addition, when the left ventricle contracts, it faces a reduced aortic pressure to work against, since the counterpulsation has somewhat emptied the aorta. EECP has been primarily investigated as a treatment for chronic stable angina.

Intra-aortic balloon counterpulsation is a more familiar, invasive form of counterpulsation that is used as a method of temporary circulatory assistance for the ischemic heart, often after an acute myocardial infarction. In contrast, EECP is thought to provide a permanent effect on the heart by enhancing the development of coronary collateral development. A full course of therapy usually consists of 35 one-hour treatments, which may be offered once or twice daily, usually five days per week. The multiple components of the procedure include the use of the device itself, finger plethysmography to follow the blood flow, continuous electrocardiograms (EKGs) to trigger inflation and deflation and optional use of pulse oximetry to measure oxygen saturation before and after treatment.
While EECP has been primarily researched as a treatment of chronic stable angina, it has also been used in patients with congestive heart failure.

**Note:** This policy only addresses the outpatient use of EECP, i.e., for the treatment of chronic stable angina or congestive heart failure. This policy does not address its use for unstable angina pectoris, acute myocardial infarction or cardiogenic shock.

**FDA or Other Governmental Regulatory Approval**
U.S. Food and Drug Administration (FDA)

A variety of EECP devices have been cleared for marketing by the FDA through the 510(k) process. Examples of EECP devices with FDA clearance are outlined in Table 1. FDA product code: DRN.

Table 1. FDA-Cleared EECP Devices

<table>
<thead>
<tr>
<th>Device</th>
<th>Manufacturer</th>
<th>Clearance Date</th>
<th>Indications</th>
</tr>
</thead>
</table>
| Renew® NCP-5 External Counterpulsation System | Renew Group (Rockville, MD)   | Dec 2015       | • Treatment of chronic stable angina refractory to optimal anti-anginal medical therapy and without options for revascularization  
|                                     |                               |                | • In healthy patients to improve vasodilation, increase VO₂, and increase blood flow |
| ECP Health System Model             | ECP Health                    | Aug 2005       | • Stable or unstable angina pectoris                                          
|                                     |                               |                | • Acute myocardial infarction                                                  
|                                     |                               |                | • Cardiogenic shock                                                           
|                                     |                               |                | • Congestive heart failure                                                    
| CardiAssist™ Counter Pulsation System | Cardiomedics (Irvine, CA)     | Mar 2005       | • Treatment of ischemic heart disease by increasing perfusion during diastole in people with chronic angina pectoris, congestive heart failure, myocardial infarction, and cardiogenic shock |
| ACS Model NCP-2 External Counterpulsation Device | Applied Cardiac Systems (Laguna Hills, CA) | Aug 2004 | • Stable or unstable angina pectoris                                          
|                                     |                               |                | • Acute myocardial infarction                                                  
|                                     |                               |                | • Cardiogenic shock                                                           
|                                     |                               |                | • Congestive heart failure                                                    
| EECP® Therapy System                | Vasomedical (Westbury, NY)    | Mar 2004       | • Stable or unstable angina pectoris                                          
|                                     |                               |                | • Acute myocardial infarction                                                  
|                                     |                               |                | • Cardiogenic shock                                                           
|                                     |                               |                | • Congestive heart failure                                                    |

EECP: enhanced external counterpulsation; FDA: Food and Drug Administration; VO₂: oxygen consumption.

Centers for Medicare and Medicaid Services (CMS)
Medicare has published a national coverage decision regarding EECP that mandates coverage for the following indications:
“Coverage is provided for the use of EECP for patients who have been diagnosed with disabling angina who, in the opinion of a cardiologist or cardiothoracic surgeon, are not readily amenable to surgical intervention, such as percutaneous transluminal coronary angioplasty or cardiac bypass because: 1) Their condition is inoperable, or at high risk of operative complications or post-operative failure; 2) Their coronary anatomy is not readily amendable to such procedures; or 3) They have co-morbid states which create excessive risk.”

Medicare’s coverage policy also notes that while the FDA has cleared EECP “for use in treating a variety of cardiac conditions, including stable or unstable angina pectoris, acute myocardial infarction and cardiogenic shock, the use of this device to treat cardiac conditions other than stable angina pectoris is not covered.”

**Rationale/Source**

The use of EECP for the treatment of disabling, chronic, stable disabling angina in patients who are not suitable candidates for surgical intervention or who have failed surgical intervention has been established in the medical evidence. Several large-scale prospective studies evaluating the efficacy of EECP in patients with chronic stable angina demonstrate significant improvements in anginal symptoms, myocardial perfusion and output. One randomized, sham-controlled trial demonstrated significant improvement at 12 months in patients who underwent a single 35-hour course of EEPC. In this study treatment-group, patients reported significant improvements compared to sham treated patients in all nine quality of life scales included on the Medical Outcomes Study SF-36 health survey, including the activities of daily living, ability to work, bodily pain and others.

EECP has also been studied for the treatment of congestive heart failure. In 2002, Soran and colleagues reported on a feasibility study of EECP as a treatment for congestive heart failure in 26 patients. In this uncontrolled study, the patients were treated with 35 daily, one-hour sessions and followed for six months after completion of the course of therapy. The study suggests that the treatment was safe and well tolerated. Based in part on the results of this study, a larger, randomized study has been launched, the PEECH trial (Prospective Evaluation of EECP in Congestive Heart Failure). Results of this trial have not yet been published.

The evidence regarding the use of EECP for other indications, including other anginal or cardiac conditions, such as including non-disabling stable angina or unstable angina is currently insufficient to allow conclusions to be made.

Studies of EECP in angina patients with severe left ventricular dysfunction suggest that improvement in anginal symptoms, as well as quality of life, are consistent, independent of degree of ventricular dysfunction, and sustainable for up to two years. Similar results were noted after one year in an observational study published in 2005 of 746 angina patients with either systolic or diastolic dysfunction who received EECP for their angina.
Enhanced External Counterpulsation (EECP)

Policy # 00036
Original Effective Date: 11/12/2001
Current Effective Date: 08/01/2018

References

2. Blue Cross and Blue Shield Technology Evaluation Center (TEC). External Counterpulsation for Treatment of Chronic Stable Angina Pectoris and Chronic Heart Failure. TEC Assessments 2005; 20(Tab 12).

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Enhanced External Counterpulsation (EECP)

Policy # 00036
Original Effective Date: 11/12/2001
Current Effective Date: 08/01/2018


Policy History
Original Effective Date: 11/12/2001
Current Effective Date: 08/01/2018

10/18/2001 Medical Policy Committee review
11/12/2001 Managed Care Advisory Council approval
06/24/2002 Format revision. No substance change to policy.
10/21/2003 Medical Policy Committee review Format revision. No substance change to policy.
01/26/2004 Managed Care Advisory Council approval
01/04/2005 Medical Director review
01/18/2005 Medical Policy committee review
01/31/2005 Managed Care Advisory council approval. Investigational policy added
05/03/2006 Medical Director review

©2018 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
Enhanced External Counterpulsation (EECP)

Policy # 00036
Original Effective Date: 11/12/2001
Current Effective Date: 08/01/2018

Coding
The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2017 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology.
Enhanced External Counterpulsation (EECP)

Policy # 00036
Original Effective Date: 11/12/2001
Current Effective Date: 08/01/2018

Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

<table>
<thead>
<tr>
<th>Code Type</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>CPT</td>
<td>92971</td>
</tr>
<tr>
<td>HCPCS</td>
<td>G0166</td>
</tr>
<tr>
<td>ICD-10 Diagnosis</td>
<td>All related diagnoses</td>
</tr>
</tbody>
</table>

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is investigational will be based on a consideration of the following:
  A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. FDA and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
  B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
     1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
     2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
     3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:
  A. In accordance with nationally accepted standards of medical practice;
  B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
  C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.